Universal adoption of pathogen inactivation of platelet components: Impact on platelet and red blood cell component use

Transfusion

Volumn 49, Issue 7, 2009, Pages 1412-1422

  Corash, Laurence ^a   Osselaer, Jean Claude ^b   Doyen, Chantal ^b   Defoin, Laurence ^b   Debry, Cecile ^b   Goffaux, Maité ^b   Messe, Nathalie ^b   Van Hooydonk, Maryse ^b   Bosly, Andre ^b   Lin, Jin Sying ^b   Lin, Lily ^b  

^a CERUS CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD BANK; BLOOD COMPONENT; BLOOD TRANSFUSION; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; THROMBOCYTE TRANSFUSION;

BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD-BORNE PATHOGENS; HUMANS; PLATELET COUNT; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES;

EID: 67649985872     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02151.x     Document Type: Article

References (18)

1. Harris SB, Hillyer CD. Blood manufacturing: component preparation, storage, and transportation. In : Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD, editors. Blood banking and transfusion medicine. 2nd ed. Philadelphia (PA) : Churchill Livingstone 2007. p. 183 204.
2. Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005 19 : 259 72.
3. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia. N Engl J Med 1997 337 : 1870 5.
4. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997 337 : 1861 9.
5. Tinmouth AT, Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev 2003 17 : 181 93.
6. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 2006 21 : 78 84.
7. Slichter SJ. Evidence-based platelet transfusion guidelines. In : Gewirtz AM, Winter JN, Zuckerman K, editors. American Society of Hematology education program book. Washington, DC : American Society of Hematology 2007. p. 172 8.
8. Osselaer J, Doyen C, Chatelain C, Debry C, Goffaux M, Messe N, Van Hooydonk M, Sonnet A, Bosly A, Lin JS, Corash L. Impact of photochemical treatment (INTERCEPT™) on platelet use in routine practice. Vox Sang 2006 91 Suppl 3 : 180.
9. Cazenave JP. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Clinical experience with pathogen-inactivated platelets. Transfusion Med Reviews 2008 22 : 1 34.
10. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies: report of a consensus conference. Transfusion 2007 47 : 2338 47.
11. van Rhenen D J, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003 101 : 2426 33.
12. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th., Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004 104 : 1534 41.
13. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005 45 : 1443 52.
14. Belgian Law of 8 December 1992 on privacy protection in relation to the processing of personal data as modified by the law of 11 December 1998 implementing Directive 95/46 EC and the law of 26 February 2003. Belgium : Belgian State Gazette 2003.
15. 111 indium radiolabeled platelets treated with pathogen inactivation using amotosalen HCl (S-59) and UVA light. Transfusion 2004 44 : 1732 440.
16. Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin JS, Corash L, Conlan MG SPRINT Study Group. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006 46 : 24 33. (Pubitemid 43381781)
17. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrón F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008 94 : 315 23.
18. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5106 platelet transfusions using components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 48 : 1061 71.